A Phase 4 interventional study of Fluticasone Propionate Nasal Spray and Saline Nasal Spray in Allergic Rhinitis and Allergic Conjunctivitis, sponsored by ORA, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.
Sponsored by ORA, Inc. · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fluticasone in Rhinitis, Allergic — none open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic.
Among the 34 studies testing fluticasone in Rhinitis, Allergic, this one is the 28th largest by enrollment, is the only one that started in 2011, is one of 19 in phase 4, and was the 25th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →None of the 34 studies testing fluticasone in Rhinitis, Allergic is open now. The open studies under Rhinitis, Allergic, anywhere →
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 63 across the 34 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
ORA, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
ORA, Inc. has 5 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fluticasone in Rhinitis, Allergic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the onset of action of fluticasone propionate nasal spray compared to placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after up to 14 days of at home dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
Drug: Saline Nasal Spray
Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
Drug: Fluticasone Propionate Nasal Spray
two sprays in each nostril once daily
Also known as: Flonase
two sprays in each nostril once daily
Change in Total Nasal Signs and Symptoms Score From Baseline (Day 0) to Visit 5 (Day 16)
The change in the total sum of the four symptoms (total nasal symptom scores - TNSS) ranging from 0 to 16 with higher score indicating a more severe reaction. The change in the TNSS score between Day 0 and Day 16 was analyzed.
Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Change in Baseline Nasal Itching Score on Day 0 to Average Nasal Itching Score on Day 16
Nasal Itching was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal itching score between Day 0 and Day 16 was analyzed.
Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Change in Baseline Sneezing Score on Day 0 to Average Sneezing Score on Day 16
Sneezing was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average sneezing score between Day 0 and Day 16 was analyzed.
Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Change in Baseline Rhinorrhea Score on Day 0 to Average Rhinorrhea Score on Day 16
Rhinorrhea was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average rhinorrhea score between Day 0 and Day 16 was analyzed.
Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Change in Baseline Nasal Congestion Score on Day 0 to Average Nasal Congestion Score on Day 16
Nasal Congestion was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal congestion score between Day 0 and Day 16 was analyzed.
Time frame: pre-ABC exposure and approximately every 15 minutes, up to 180 minutes, while in the ABC on Day 0 and Day 16
Subjects were recruited from one site in the US.
| Milestone | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Started | 11 | 11 |
| All randomized participant population | 11 | 11 |
| Completed | 11 | 9 |
| Not completed | 0 | 2 |
The change in the total sum of the four symptoms (total nasal symptom scores - TNSS) ranging from 0 to 16 with higher score indicating a more severe reaction. The change in the TNSS score between Day 0 and Day 16 was analyzed.
| units on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| pre-ABC | -0.7 ± 1.8 | 0.3 ± 1.8 |
| 15 minutes | -2.8 ± 3.4 | 0.9 ± 3.8 |
| 30 minutes | -4.1 ± 3.4 | -0.6 ± 3.0 |
| 45 minutes | -3.9 ± 4.2 | -0.3 ± 3.1 |
| 60 minutes | -4.7 ± 3.6 | -0.9 ± 3.3 |
| 75 minutes | -4.5 ± 4.5 | -2.3 ± 3.7 |
| 90 minutes | -4.5 ± 4.3 | -1.7 ± 3.3 |
| 105 minutes | -5.0 ± 4.0 | -1.6 ± 2.5 |
| 120 minutes | -5.9 ± 3.1 | -0.7 ± 3.5 |
| 135 minutes | -4.8 ± 4.0 | -0.5 ± 3.2 |
| 150 minutes | -5.3 ± 3.6 | -1.7 ± 2.6 |
| 165 minutes | -5.4 ± 3.2 | -1.6 ± 2.8 |
| 180 minutes | -5.9 ± 3.0 | -0.6 ± 3.0 |
Nasal Itching was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal itching score between Day 0 and Day 16 was analyzed.
| units on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Pre-ABC | -0.2 ± 0.6 | 0.1 ± 0.7 |
| 15 minutes | -1 ± 1 | 0.3 ± 0.8 |
| 30 minutes | -1 ± 1.2 | -0.1 ± 0.6 |
| 45 minutes | -0.8 ± 1.6 | -0.1 ± 0.9 |
| 60 minutes | -1.3 ± 1.3 | -0.3 ± 0.9 |
| 75 minutes | -1.3 ± 1.5 | -0.5 ± 0.8 |
| 90 minutes | -1 ± 1.6 | -0.6 ± 0.7 |
| 105 minutes | -1.3 ± 1.3 | -0.5 ± 0.8 |
| 120 minutes | -1.5 ± 1.1 | -0.4 ± 0.8 |
| 135 minutes | -1.5 ± 1.2 | -0.3 ± 0.8 |
| 150 minutes | -1.5 ± 1.3 | -0.2 ± 0.8 |
| 165 minutes | -1.5 ± 1.1 | -0.2 ± 1 |
| 180 minutes | -1.8 ± 1.2 | 0 ± 1.1 |
Sneezing was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average sneezing score between Day 0 and Day 16 was analyzed.
| units on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Pre-ABC | -0.1 ± 0.3 | 0.2 ± 0.9 |
| 15 minutes | -0.5 ± 1.1 | 0.1 ± 0.9 |
| 30 minutes | -0.9 ± 0.8 | -0.4 ± 0.8 |
| 45 minutes | -0.9 ± 1.1 | 0 ± 0.9 |
| 60 minutes | -1.3 ± 1.1 | -0.2 ± 1 |
| 75 minutes | -1.1 ± 1.3 | -0.6 ± 1.3 |
| 90 minutes | -1.1 ± 1.4 | -0.3 ± 1.2 |
| 105 minutes | -1.2 ± 1.1 | -0.4 ± 1 |
| 120 minutes | -1.3 ± 1.3 | -0.1 ± 1.1 |
| 135 minutes | -0.9 ± 1.4 | 0 ± 0.9 |
| 150 minutes | -0.8 ± 1.3 | -0.7 ± 1 |
| 165 minutes | -1.1 ± 0.9 | -0.6 ± 1 |
| 180 minutes | -1.2 ± 0.8 | -0.1 ± 0.7 |
Rhinorrhea was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average rhinorrhea score between Day 0 and Day 16 was analyzed.
| units on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Pre-ABC | -0.4 ± 0.8 | 0 ± 0.5 |
| 15 minutes | -0.9 ± 0.9 | 0.4 ± 1.2 |
| 30 minutes | -1.5 ± 0.8 | 0 ± 0.8 |
| 45 minutes | -1.1 ± 1.1 | -0.2 ± 1 |
| 60 minutes | -1.2 ± 1 | -0.1 ± 1 |
| 75 minutes | -1.3 ± 1.1 | -0.7 ± 1.3 |
| 90 minutes | -1.5 ± 1 | -0.5 ± 1.1 |
| 105 minutes | -1.4 ± 1.4 | -0.5 ± 1 |
| 120 minutes | -1.7 ± 0.6 | -0.1 ± 1 |
| 135 minutes | -1.4 ± 1.1 | 0 ± 1.1 |
| 150 minutes | -1.5 ± 0.8 | -0.4 ± 0.8 |
| 165 minutes | -1.4 ± 0.8 | -0.4 ± 0.8 |
| 180 minutes | -1.5 ± 0.9 | -0.3 ± 1.2 |
Nasal Congestion was assessed by the participants pre-ABC exposure and approximately every 15 minutes while in the ABC on Day 0 and Day 16 on a 0-4 scale (0 = none to 4 = severe). The change in average nasal congestion score between Day 0 and Day 16 was analyzed.
| units on a scale | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| Pre-ABC | -0.1 ± 1 | 0 ± 0.7 |
| 15 minutes | -0.4 ± 1.2 | 0.1 ± 1.3 |
| 30 minutes | -0.7 ± 1.3 | -0.1 ± 1.2 |
| 45 minutes | -1.1 ± 1.1 | 0 ± 0.9 |
| 60 minutes | -1 ± 1.1 | -0.4 ± 0.8 |
| 75 minutes | -0.9 ± 1.1 | -0.5 ± 1 |
| 90 minutes | -1.1 ± 1.2 | -0.3 ± 0.9 |
| 105 minutes | -1.2 ± 1 | -0.2 ± 0.9 |
| 120 minutes | -1.5 ± 0.9 | -0.2 ± 0.9 |
| 135 minutes | -1.1 ± 1.1 | -0.2 ± 0.9 |
| 150 minutes | -1.4 ± 0.9 | -0.3 ± 0.8 |
| 165 minutes | -1.4 ± 0.9 | -0.3 ± 0.8 |
| 180 minutes | -1.5 ± 0.9 | -0.1 ± 0.9 |
Collected over Adverse events were collected from baseline (Day 0) through study completion (Day 16). All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Propionate Nasal Spray | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Placebo Nasal Spray | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Event | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray |
|---|---|---|
| hives (neck)General disorders | 0/11 | 1/11 |
| dizzinessGeneral disorders | 1/11 | 0/11 |
| headacheGeneral disorders | 0/11 | 1/11 |
| hives (face)General disorders | 0/11 | 1/11 |
| Age, Categorical(Participants) | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 11 | 22 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Fluticasone Propionate Nasal Spray | Placebo Nasal Spray | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 5 | 5 | 10 |
The record gives a start of Sep 2011, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2021, 9 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone